James J. Cava's most recent trade in Cypherpunk Technologies Inc. was a trade of 94,050 Restricted Stock Units done . Disclosure was reported to the exchange on March 13, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Leap Therapeutics Inc | James H. Cavanaugh | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2026 | 94,050 | 0 | - | - | Restricted Stock Units | |
| Leap Therapeutics Inc | James H. Cavanaugh | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2026 | 94,050 | 168,963 (0%) | 0% | - | Common Stock | |
| Leap Therapeutics Inc | James H. Cavanaugh | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2026 | 74,700 | 74,913 (0%) | 0% | - | Common Stock | |
| Leap Therapeutics Inc | James H. Cavanaugh | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2026 | 74,700 | 0 | - | - | Restricted Stock Units | |
| Leap Therapeutics Inc | James H. Cavanaugh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2025 | 94,050 | 94,050 | - | - | Restricted Stock Units | |
| Leap Therapeutics Inc | James H. Cavanaugh | Director | Sale of securities on an exchange or to another person at price $ 3.14 per share. | 17 Nov 2025 | 261,840 | 0 (0%) | 1% | 3.1 | 822,178 | Common Stock |
| Leap Therapeutics Inc | James H. Cavanaugh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Nov 2025 | 74,700 | 74,700 | - | - | Restricted Stock Units | |
| Leap Therapeutics Inc | James H. Cavanaugh | Director | 13 Nov 2024 | 213 | 213 (0%) | 0% | 2.8 | 601 | Common Stock | |
| Leap Therapeutics Inc | James H. Cavanaugh | Director | 13 Nov 2024 | 213 | 0 | - | - | Warrant (Right to Buy) | ||
| Leap Therapeutics Inc | James H. Cavanaugh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Oct 2024 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Leap Therapeutics Inc | James H. Cavanaugh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2024 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Leap Therapeutics Inc | James H. Cavanaugh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Leap Therapeutics Inc | James H. Cavanaugh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Leap Therapeutics Inc | James H. Cavanaugh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) |